INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22.00 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions.

INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING

With XPro1595, it has a disease-modifying drug candidate that has already shown to consistently decrease multiple biomarkers of neuroinflammation; The test is now how this affects biomarkers of neurodegeneration and AD; readout to be expected in August 2021;

INmune Bio: Underfollowed AD Player With Very Bullish August Momentum

The stock price of INmune Bio Inc (NASDAQ: INMB) increased by 10.64%. This is why it happened.

INmune Bio Stock Increased 10.64%: Why It Happened

Purchase of Xencor Option potentially eliminates approximately 2.1  mill ion shares of INmune future common stock dilution upon ﻿execution.﻿

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE) --  -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today that the United States Adopted Name Council (USAN) has adopted the name “Pegipanermin” for its lead clinical candidate, XPro1595.

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today that RJ Tesi, MD, chief executive officer, has been invited to present at Alzheimer Disease Panel, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday May 26th, 2021.

INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021

INmune Bio, Inc. (INMB) CEO RJ Tesi on Q1 2021 Results - Earnings Call Transcript

Company to host conference call today, May 5, at 4:30pm ET Company to host conference call today, May 5, at 4:30pm ET

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

Management to host conference call at 4:30 pm ET on that day Management to host conference call at 4:30 pm ET on that day

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5

LA JOLLA, Calif, April 26, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will participate in a fireside chat at the B Riley Neuroscience Conference on Wednesday, April 28.

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference

Based on the theory that chronic low-grade inflammation is behind many ailments, the company's therapies are setting out to enlist the innate immune system to combat these.

INmune Bio: Harnessing The Power Of The Innate Immune System

The stock price of INmune Bio Inc (NASDAQ: INMB) increased by over 3% pre-market. This is why it happened.

INMB Stock: Over 3% Increase Pre-Market Explanation

Innate Killer Digital Summit 2021, which is being held March 23-25

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

INmune Bio, Inc. (INMB) CEO RJ Tesi on Q4 2020 Results - Earnings Call Transcript

Company to host conference call today, March 4, at 4:30pm ET Company to host conference call today, March 4, at 4:30pm ET

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update

The wild ride for the biotech stock started with its announcement of results from a phase 1b study.

Why INmune Bio Stock Soared Then Sank Today

Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer's Disease in Phase 1b Trial

Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer's disease

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Inmune Bio Inc. (NASDAQ:INMB)? The smart money sentiment can provide an answer to this question.

Do Hedge Funds Love Inmune Bio Inc. (INMB)?

Disney

Microchip Technology

Maxim Integrated Products

National General Holdings

NXP Semiconductors

Palantir Technologies

PPG Industries

Unity Software

Varian Medical Systems

In this article we present the list of Top 10 Stocks Billionaire George Soros Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire George Soros Just Bought .

Top 10 Stocks Billionaire George Soros Just Bought

LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating Quellor™ for the treatment of pulmonary complications from COVID-19. Quellor™ is a selective soluble Tumor Necrosis Factor (sTNF) inhibitor designed to potentially prevent the progression of immune mediated pulmonary complications resulting from SARS-CoV-2 viral infection.

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients

INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript

Management to host conference call at 4:30 pm ET on that day

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced  that CJ Barnum PhD, Head of Neurosciences will present data from the ongoing biomarker directed Phase Ib study of neuroinflammation in patients with Alzheimer’s disease.  The talk entitled, Phase 1b Study in AD Patients with Neuroinflammation​, will be given today at 11:20AM ET as part of this year’s virtual 21st International Conference on Alzheimer’s Drug Discovery meeting.  The trial continues to enroll patients and additional data on the Phase Ib study will be presented in the near future.

News for INmune Bio Inc Stock (INMB)